New antiepileptic drugs currently in clinical trials: is there a strategy in their development?
In designing and developing antiepileptic drugs (AEDs), attention should be paid to the desirable pharmacokinetic properties of potential new agents so that molecules are designed to achieve the desired pharmacodynamic and pharmacokinetic profiles. A review of current compounds in development or in clinical trials shows that several promising agents have incorporated pharmacokinetic-based design into their development process. This is particularly true for new AEDs that are second-generation or follow-up compounds of existing AEDs.
Bialer
Meir
M
Department of Pharmaceutics and David R. Bloom Center, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel. bialer@md.huji.ac.il
D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004827:Epilepsy / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D014635:Valproic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D000927:Anticonvulsants; D014635:Valproic Acid